Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Update

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a significant decrease in short interest in October. As of October 31st, there was short interest totalling 200 shares, a decrease of 86.7% from the October 15th total of 1,500 shares. Based on an average daily volume of 2,300 shares, the short-interest ratio is presently 0.1 days.

Clinuvel Pharmaceuticals Trading Up 0.1 %

Shares of CLVLY traded up $0.01 during mid-day trading on Wednesday, reaching $8.95. 1,450 shares of the company’s stock were exchanged, compared to its average volume of 2,716. The company has a 50-day simple moving average of $9.57 and a two-hundred day simple moving average of $9.76. Clinuvel Pharmaceuticals has a 52-week low of $8.42 and a 52-week high of $12.06.

Clinuvel Pharmaceuticals Increases Dividend

The business also recently disclosed a dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were paid a dividend of $0.0299 per share. The ex-dividend date was Monday, September 9th. This is a positive change from Clinuvel Pharmaceuticals’s previous dividend of $0.03.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).